AACR: Bristol-Myers Squibb's Opdivo-Yervoy duo provokes response in rare tumors

opdivo
Bristol-Myers Squibb's Opdivo and Yervoy spurred a response in 24% of patients in a phase 2 study. (Bristol-Myers Squibb)

ATLANTA—Bristol-Myers Squibb has found success with its Opdivo-Yervoy combo in treating various common tumors. But it turns out the duo can help some patients with rare tumors, too.

Sunday at the American Association for Cancer Research annual meeting, researchers unveiled data from an investigator-sponsored phase 2 study showing Opdivo and Yervoy could produce a benefit in patients with neuroendocrine tumors in various parts of the body.

In a study of 33 patients, 24% responded to therapy, with one patient’s cancer disappearing completely. But among patients with high-grade cancer cells—which tend to grow and spread more quickly—response figures were higher: 42%, or 8 of 19 patients, recorded a response to the combo, while none of the patients with low- or intermediate-grade cancer did.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Based on those numbers, researchers concluded that “further investigation of this combination is warranted,” they said in the study abstract. And meanwhile, they have an idea as to why the BMS pairing only turned up a benefit in high-grade patients.

“One preliminary hypothesis for this finding is that high-grade neuroendocrine carcinomas may have a higher tumor mutational burden (TMB), which is an indicator of better response to immunotherapy,” lead study investigator Sandip Patel, M.D., said in a statement.

RELATED: BMS' Opdivo-Yervoy combo posts big win in first-line lung cancer—but big enough to challenge Merck?

Bristol-Myers itself has been working to prove the link between TMB and Opdivo-Yervoy efficacy as it chases an indication in previously untreated non-small cell lung cancer, which is considered immuno-oncology’s largest market. After trumpeting positive data at last year’s AACR meeting, the company in October acknowledged that in a new analysis, the combo’s survival benefit in patients with high TMB and low TMB appeared “quite similar (based on hazard ratios compared to chemotherapy),” as Credit Suisse analyst Vamil Divan put it.

“This leads us to wonder why regulators would approve the regimen strictly for patients with high TMB as per the current filing,” he wrote at the time. And Bristol didn’t wait to find out: It pulled its application in January, citing a need for more data.

RELATED: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?

Meanwhile, though, Patel and his colleagues say they’ve already scored with the study. “Our study highlights the feasibility of performing clinical trials among patients with rare cancers,” he said, noting rare tumor types represent “nearly a quarter of all cancers.”

The study “hopefully will help dispel the belief that clinical trials are not feasible for this patient population,” he added.

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.

Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.